Inorganic nitrate, hypoxia, and the regulation of cardiac mitochondrial respiration-probing the role of PPARα. by Horscroft, James A et al.
 
 
INORGANIC NITRATE, HYPOXIA AND THE REGULATION OF 







 Anna D. Clark,
1











 Stephen D.R. Harridge
2
 




Department of Physiology, Development & Neuroscience, University of Cambridge, UK 
2 
Centre for Human and Applied Physiological Sciences, King’s College London, London, 
UK 
3





For correspondence:  Dr Andrew Murray 
Department of Physiology, Development & Neuroscience 





  Telephone: (+44 1223) 333863 
  Email:  ajm267@cam.ac.uk 
 
 
Running title: Nitrate, hypoxia and cardiac mitochondrial function 
  




BIOPS  biopsy preservation solution 
cGMP  cyclic guanosine monophosphate 
CPT  carnitine palmitoyltransferase 
CS  citrate synthase 
eNOS  endothelial nitric oxide synthase 
ETS  electron transfer system 
FAO  fatty acid oxidation 
HADH  3-hydroxyacyl dehydrogenase 
HFrEF  heart failure with reduced ejection fraction 
HIF  hypoxia-inducible factor  
LDH  lactate dehydrogenase 
LEAK  leak respiration 
NO  nitric oxide 
NO2
-
  nitrite 
NO3
-
  nitrate 







OXPHOS oxidative phosphorylation 
PGC1α peroxisome proliferator-activated receptor gamma co-activator 1α 
PKG  cGMP-dependent protein kinase G 
PPAR  peroxisome proliferator-activated receptor 
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PDH  pyruvate dehydrogenase 
PDK  pyruvate dehydrogenase kinase 
ROS  reactive oxygen species 
sGC  soluble guanylyl cyclase  




Dietary inorganic nitrate prevents aspects of cardiac mitochondrial dysfunction induced by 
hypoxia, although the mechanism is not completely understood. In both heart and skeletal 
muscle, nitrate increases fatty acid oxidation capacity, and in the latter case this involved 
upregulation of PPARα expression. Here we investigated whether dietary nitrate modifies 
mitochondrial function in the hypoxic heart in a PPARα-dependent manner. Wild-type and 
Ppara
-/-
 mice were given water containing 0.7 mM NaCl (control) or 0.7 mM NaNO3 for 35 
d. After 7 d, mice were exposed to normoxia or hypoxia (10% O2) for the remainder of the 
study. Mitochondrial respiratory function and metabolism were assessed in saponin-
permeabilised cardiac muscle fibres. Environmental hypoxia suppressed mass-specific 
mitochondrial respiration, and additionally lowered the proportion of respiration supported by 
fatty acid oxidation by 18% (P < 0.001). This switch away from fatty acid oxidation was 
reversed by nitrate treatment in hypoxic wild-type but not Ppara
-/-
 mice, indicating a PPARα-
dependent effect. Hypoxia increased hexokinase activity by 33% in all mice, whilst lactate 
dehydrogenase activity increased by 71% in hypoxic wild-type but not Ppara
-/-
 mice. Our 
findings indicate that PPARα plays a key role in mediating cardiac metabolic remodelling in 
response to both hypoxia and dietary nitrate supplementation. 
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The mammalian heart is often described as a metabolic omnivore, in reference to its ability to 
oxidise a variety of substrates in order to meet ATP demands (1). Whilst the healthy heart 
predominantly uses fatty acid oxidation (FAO) to meet these requirements under fasting 
conditions, under hypoxic conditions FAO is downregulated in favour of a relative increase 
in glucose metabolism (2), which requires less O2 per ATP synthesised (1). Key to this 
response is a reduction in the expression of peroxisome proliferator-activated receptor 
(PPAR)α, a ligand-activated transcription factor expressed in liver, heart, kidney, and to a 
lesser extent skeletal muscle (3). When activated, PPARα increases the expression of a 
number of genes involved in mitochondrial fatty acid import (e.g. Cpt1b) and β-oxidation 
(e.g. Hadh, Acadm, Ucp3) (3). In mice, cardiac-specific ablation of Arnt, which encodes 
hypoxia-inducible factor (HIF)-1β, increased PPARα expression and transcriptional activity, 
increasing FAO (4), suggesting that HIF signalling attenuates PPARα in hypoxia. Indeed, in 
cardiomyocytes HIF-1α activation decreased PPARα DNA binding activity (5). In addition to 
a suppression of FAO, mitochondrial pyruvate oxidation is also suppressed in hypoxia via the 
phosphorylation of pyruvate dehydrogenase (PDH) by pyruvate dehydrogenase kinase 1 
(PDK1), which is induced by HIF-1α in hypoxic cells (6, 7). Thus mitochondrial respiration 
would be suppressed in favour of glycolytic ATP production. 
In the hypoxic rodent heart, the transcriptional activity of PPARα is downregulated in 
association with a suppression of FAO (8, 9) and an increase in glycolysis (8). As such, the 
cardiac metabolic phenotype of hypoxic mice resembles that of Ppara
-/-
 mice, and notably, no 
further suppression of FAO occurs in Ppara
-/-
 mice following exposure to hypoxia (8). 
Moreover, whilst hypoxic exposure results in an impaired cardiac energetic reserve in both 
humans (10) and rodents (8), increasing PPARα activity and FAO in hypoxic mice through a 
high-fat diet did not improve energetics and in fact worsened contractile function (8), thus it 
appears that downregulation of FAO in the hypoxic heart is protective. Recent work, 
however, has suggested that both FAO and energetics might be preserved in hypoxic tissues 
by dietary supplementation with inorganic nitrate (NO3
-
). 
Dietary inorganic nitrate (NO3
-
) is principally acquired through the consumption of leafy, 
green vegetables and has effects on mitochondrial function which may be beneficial to 
human health (11). Nitrate is reduced to nitrite (NO2
-
) via oral nitrate reductase in commensal 
bacteria (12). Nitrite is then converted to nitric oxide (NO) in the stomach by acid 
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disproportionation (13), and is absorbed into the bloodstream where it can be oxidised to 
nitrite by ceruloplasmin (14) or to nitrate by haemoglobin (15). Under conditions of moderate 
hypoxia and/or acidosis, nitrite may be reduced to NO by one of several nitrite reductases, 
including xanthine oxidoreductase (16), deoxyhaemoglobin (17), deoxymyoglobin (18) and 
endothelial nitric oxide synthase (eNOS) (19). Under such conditions, endogenous NO 
production from L-arginine and O2 via the nitric oxide synthase (NOS) enzymes is attenuated 
due to the low partial pressure of O2, thus nitrate supplementation may prevent a hypoxia-
induced fall in NO bioavailability. 
A major physiological role of NO is to induce vasodilatation upon its release from the 
endothelium in response to a range of stimuli (20). NO binds to the haem group of soluble 
guanylyl cyclase (sGC) inducing cGMP production (21). This in turn activates cGMP-
dependent protein kinase G (PKG), which results in smooth muscle relaxation and 
vasodilatation via a reduction in intracellular [Ca
2+
] (22), thus enhancing blood flow and O2 
delivery. Additionally, supplementation with moderate doses of dietary nitrate partially 
offsets the rise in circulating erythropoietin and haemoglobin in hypoxic rats (23), which 
might prevent the microcirculatory dysfunction associated with an increased haematocrit (24) 
further improving O2 delivery. Indeed, native Tibetan highlanders have high levels of plasma 
nitrate (25) and lower blood haemoglobin concentrations than acclimatised lowlanders at any 
given altitude (26), and this is associated with superior forearm blood flow (25). 
Supplementation of dietary nitrate under hypoxic conditions may therefore preserve O2 
delivery to respiring tissues. 
In addition to effects on O2 delivery though, NO regulates multiple aspects of oxidative 
metabolism in respiring tissues. NO induces mitochondrial biogenesis through the 
upregulation of PPARγ co-activator-1α (PGC1α) (27). Within mitochondria, NO competes 
with O2 at complex IV of the electron transfer system (ETS), leading to partial inhibition of 
electron transport and control over reactive oxygen species (ROS) signalling (28). NO also 
reacts with the superoxide ion (O2
.-
) to form peroxynitrite (ONOO
.-
) (29), which acts as an 
endogenous toxicant (30). Moreover, NO can induce a post-translational modification of 
complex I via S-nitrosation, resulting in its inhibition (31), which has implications both for 
respiratory function and ROS production.  
It has been reported that supplementation with dietary nitrate lowers the O2 cost of exercise in 
humans (32) by increasing mitochondrial thermodynamic efficiency (11), and accordingly 
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nitrate could be beneficial in hypoxia. In the hypoxic rat heart, nitrate supplementation 
prevented the downregulation of ETS complex I expression and activity and the depression of 
mitochondrial FAO, whilst lowering markers of oxidative stress and protecting ATP levels 
(33). It is not clear, however, whether this nitrate-mediated protection resulted from a direct 
effect on the cardiomyocyte or through improvements in O2 delivery that offset the challenge 
of hypoxia. Notably, however, nitrate supplementation enhanced mitochondrial FAO capacity 
in both the heart (33) and skeletal muscle (34) of normoxic rats. Mechanistically, nitrate 
increased PPARα transcriptional activity in skeletal muscle, with no increase in FAO seen in 
Ppara
-/-
 mice (34). Moreover, a similar effect on PPARα transcription was seen in cultured 
myocytes under constant, well-oxygenated conditions (34), suggesting a role for nitrate 
supplementation beyond any influence of NO on haemodynamics. 
Dietary nitrate therefore protects β-oxidation in the hypoxic heart (33), and increases β-
oxidation in skeletal muscle via PPARα activation (34). PPARα transcriptional activity is 
suppressed in the hypoxic rodent heart, although expression of PPARα itself may be 
unchanged (9). The interaction between nitrate and PPARα in the hypoxic heart, however, 
remains unclear, and specifically it is not known whether PPARα is essential for the 
protective effects on mitochondrial respiratory function and FAO elicited by nitrate. We 




 mice, exposed to 
environmental hypoxia or normoxia, with and without supplementation with a moderate 
concentration of dietary nitrate. We previously reported that nitrate protected aspects of 
skeletal muscle mitochondrial respiratory function in these mice in hypoxia, and found this 
occurred independently of PPARα (35). However, it has been suggested that in the skeletal 
muscle of Ppara
-/-
 mice, high expression of PPARβ/δ compensates for the loss of PPARα 
(36). Moreover, expression of PPARα is higher in heart than skeletal muscle (3). Here we 
focussed on the role of PPARα in nitrate-mediated effects on the hypoxic heart, 
hypothesising that nitrate regulates mitochondrial function and β-oxidation in the hypoxic 
heart in a manner dependent upon PPARα activity. 
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Materials and Methods 
Animal work was carried out in accordance with UK Home Office regulations under the 
Animals in Scientific Procedures Act, and underwent review by the University of Cambridge 
Animal Welfare and Ethical Review Committee. Procedures involving live animals were 
carried out by a licence holder in accordance with these regulations. 
Study design 
The overall study design has been described previously (35). Mice were bred on a pure 





 mice were a kind gift of Frank Gonzalez (National Institutes of 
Health, Bethesda, MD). Mice were housed in a temperature, humidity and light controlled 
environment (23°C) from birth with a 12 h/12 h light/dark cycle. Normoxic mice were 
housed under the same environmental conditions as those in the hypoxia chamber. Mice were 
provided with a standard quality-controlled diet RM1(E) (65.0% carbohydrate, 13.1% crude 
protein, 3.5% crude fat, 10 mg/kg nitrate, trace nitrite, Special Diet Services) and distilled 
water ad libitum. At six weeks of age, mice from each genotype were randomly assigned to 
receive sodium chloride (0.7 mM) as a control or sodium nitrate (0.7 mM NaNO3) in their 
drinking water. After a further 7 d, mice from each genotype/treatment combination were 
equally and randomly assigned to remain under normoxic conditions (21% O2) or transferred 
to hypoxic (10% O2) conditions in a hypoxia chamber (PFI Systems Ltd., Milton Keynes, 
UK). Mice were maintained under these conditions for 28 d (Fig. 1). Body mass, food intake 
and water intake was measured weekly. 
Mice were killed 80 ± 4 d after birth by dislocation of the neck. The chest cavity was opened 
and the heart removed and immediately placed in ice-cold biopsy preservation medium 
(BIOPS), comprising 2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 6.56 mM MgCl2.6H2O, 20 
mM taurine, 15 mM phosphocreatine, 20 mM imidazole, 0,5 mM dithiothreitol, 50 mM 
MES, 5.77 mM Na2ATP, pH 7.1. The heart was blotted and trimmed of extraneous tissue 
before being separated into three sections: the apex was kept in ice-cold BIOPS for high-
resolution respirometry, while the middle section and base were snap-frozen in liquid 
nitrogen. Meanwhile, a droplet of blood was collected from the tail vein and loaded into a 
microcuvette to quantify blood-haemoglobin concentration ([Hb]b) using a HemoCue Hb 201 
Analyzer (Quest Diagnostics, Sweden).  
 




Muscle fibre bundles were dissected from the heart and permeabilised using saponin as 
described previously (37). Mitochondrial respiratory function was assessed at 37°C using an 
Oxygraph-2K (Oroboros Instruments, Innsbruck, Austria) in respiratory medium comprising 
0.5 mM EGTA, 3 mM MgCl2.6H2O, 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 1 
mg/ml BSA, 60 mM K-lactobionate, 110 mM sucrose, pH 7.1. Respiratory medium was 
hyperoxygenated at the start of each experiment and periodically throughout each assay by 
lifting the stopper of the oxygraph chamber slightly to introduce a gas phase, before injecting 
pure O2 gas into the gas phase and then re-sealing the chamber once the desired O2 
concentration was reached. O2 concentration in the chambers was thus maintained between 
250 and 500 µM in order to negate limitations associated with O2 diffusion (37) and all 
reported respiratory fluxes were recorded within this range. 
Two substrate-inhibitor titration assays were performed to investigate respiratory control of 
different components of the mitochondrial system (Table 1).  Assay 1 was based on a 
previously described protocol (38) with the concentrations optimised for permeabilised 
cardiac fibres, and was designed to investigate β-oxidation of fatty acids. Assay 2 was 
adapted from a previously described protocol (39) and aimed to characterise control of 
different substrate-supported pathways over oxidative phosphorylation.  
Assay 1 
The addition of malate (2 mM), plus substrates for carnitine palmitoyltransferase 1 (CPT1), 
palmitoyl coenzyme A (40 μM) and carnitine (5 mM), resulted in LEAK respiration 
constrained by the activity of CPT1 (CPT1L). ADP (10 mM) resulted in oxidative 
phosphorylation (OXPHOS) also constrained by CPT1 (CPT1P). In order to bypass CPT1 and 
investigate β-oxidation capacity (PalMP), palmitoyl carnitine (20 μM) was added. Finally, 
cytochrome c (10 μM) was added to assess the integrity of the outer mitochondrial 
membrane. 
Assay 2 
Administration of octanoyl carnitine (0.2 mM) with malate (2 mM) resulted in LEAK 
respiration (OctML). ADP (10 mM) addition resulted in OXPHOS respiration dependent on 
β-oxidation of medium chain fatty acids (OctMP). Pyruvate (5 mM) was then added (PMP), 
followed by glutamate (10 mM) to support electron flux through the N-pathway via complex 
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I (GMP). Succinate (10 mM) was then administered to additionally support electron flux 
through the S-pathway via complex II (GMSP). Following this, cytochrome c (10 μM) was 
added to assess mitochondrial membrane integrity, before rotenone (0.5 μM) was 
administered to inhibit complex I and restrict electron flux to the S-pathway via complex II 
(SP). 
Coupling control ratios 
In both assays, the OXPHOS coupling efficiency (j), i.e. the proportion of OXPHOS capacity 





j OXPHOS coupling efficiency 
𝐿 LEAK respiration rate 
P OXPHOS respiration rate 
Equation 1. OXPHOS coupling efficiency 
Substrate control ratios 
The control of CPT1 over β-oxidation was assessed from Assay 1, by expressing CPT1-





Equation 2. Flux control of CPT1 over β-oxidation 
From Assay 2, OXPHOS supported by the F-Pathway (via β-oxidation), the N-pathway (via 
complex I) and the S-pathway (via complex II) were expressed as a ratio of maximal 





Equation 3. Flux control of F-pathway (via β-oxidation) over OXPHOS 




Equation 4. Flux control of N-pathway (via complex I) over OXPHOS 








Equation 5. Flux control of S-pathway (via complex II) over OXPHOS 
Finally, the ratio of OXPHOS supported by octanoyl carnitine and malate to OXPHOS 
supported by pyruvate and malate in Assay 2 was used as an indicator of the relative capacity 





Equation 6. OXPHOS capacity for fatty acid oxidation relative to pyruvate oxidation  
Enzyme activity assays 
Cardiac muscle homogenates were prepared from the contents of the oxygraph chamber. In 
brief, the entire contents of each chamber were removed and the chambers washed with 2 ml 
respiratory medium. The original contents and wash were combined with 2 μl protease 
inhibitor (cOmplete Protease Inhibitor Cocktail, Roche) and 40 μl Triton X-100 (1%). The 
solution was then homogenised using a Polytron (25,000 rpm, 30 sec) (PT-10-35 GT 
Kinematic Inc., Switzerland). The homogenate was centrifuged (10,000 rpm, 10 min, 4˚C) 
and the supernatant removed and stored at -80˚C until use. 
In addition, whole tissue homogenates were prepared. Approximately 10 mg of cardiac 
muscle from the mid-section of the heart was homogenised with an Eppendorf pestle in an 
Eppendorf tube containing 300 μl of homogenisation buffer (20 mM HEPES, 1 mM EDTA, 
0.1% Triton X-100, pH 7.2). The samples were then centrifuged (1,000 × g, 30 s, 4°C) and 
the supernatant collected. 
Protein concentration of chamber and tissue homogenates was measured using the Quick 
Start Bradford protein assay (Bio Rad). 
Enzyme activity assays were carried out at 37°C using an Evolution 220 spectrophotometer 
(Thermo Scientific). Cardiac citrate synthase activity was quantified using a method 
described previously (40) with a sample size of 10 μg protein. The assay buffer contained 20 
mM Tris, 5,5’dithiobis2-nitrobenzoicacid and 0.3 mM acetyl CoA, pH 8.0. The reaction was 
initiated by the addition of 0.5 mM oxaloacetate and absorbance change at 412 nm was 
measured.  
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Activity of the β-oxidation enzyme 3-hydroxyacyl dehydrogenase (HADH) was measured as 
described previously (41) with a sample size of 20 μg protein. The assay buffer contained 50 
mM imidazole, 0.15 mM NADH and 0.1% Triton X-100, pH 7.4 Recording of absorbance 
change at 340 nm was initiated 10 s after addition of 0.1 mM acetoacetyl coenzyme A. 
Hexokinase activity was measured with a sample size of 60 μg protein as described 
previously (42). The assay buffer contained 20 mM imidazole, 1 mM ATP, 5 mM 
7H2O.MgCl, 5 mM dithiothreitol (DTT), 2 mM NAD
+
 and 3.125 U glucose-6-phosphate 
dehydrogenase, pH 7.4. Recording of absorbance change at 340 nm was initiated 10 s after 
addition of 5 mM glucose. 
Activity of lactate dehydrogenase (LDH) was quantified essentially as described previously 
(41) with a sample size of 2 μg protein. The assay buffer contained 50 mM HEPES and 0.3 
mM NADH, pH 7.0. Recording of absorbance change at 340 nm was initiated 10 s after 
addition of pyruvate. 
Pyruvate dehydrogenase expression and phosphorylation 
Samples of left ventricle that had been snap frozen in liquid nitrogen were added to 100-150 
µl NP40 cell lysis buffer (ThermoFisher Scientific, US) containing Halt™ protease and 
phosphatase inhibitor cocktail (ThermoFisher Scientific, US). Samples were manually 
crushed then homogenised on ice using a Pellet Pestle (Sigma-Aldrich, UK). Homogenates 
were then snap frozen using liquid nitrogen and allowed to thaw on ice, after which they were 
homogenised for a second time. Samples underwent a further two freeze thaw cycles using 
liquid nitrogen, vortexing each time, before centrifugation at 16,700 x g for 10 min at 4°C. 
Supernatants were collected and stored at -80°C. Protein concentration was determined using 
the Bio-Rad DC Assay (Bio-Rad, US). Samples were loaded into Laemmli buffer at a 
concentration of 1.5 mg/ml and underwent SDS-PAGE using 10% acrylamide gels under 
reducing conditions for approximately 1 h at 0.08 A, after which they were transferred onto 
PVDF membrane (GE Healthcare, UK) for approximately 1.5 h at 0.38 A. Membranes were 
subsequently blocked for a minimum of 2 h in either 5% (w/v) bovine serum albumin or 
skimmed milk in TBS-T, as appropriate. Primary antibody targets were Phospho(serine 232)-
PDH (1:2000, Calbiochem), Phospho(serine 293)-PDH (1:1000, Abcam), Phospho(serine 
300)-PDH (1:1000, Calbiochem), PDH (1:1000, Cell Signaling Technology), and β-actin 
(1:5000, Sigma). Secondary detection was carried out using HRP-conjugated goat anti-rabbit 
(1:1000, Cell Signaling Technology) or goat anti-mouse (1:1500, Dako) antibodies. 
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Membranes were developed using Pierce™ ECL western blotting substrate (ThermoFisher 
Scientific, US) and images captured using a ChemiDoc-It2 imager (Ultra-Violet Products 
Ltd, US) with VisionWorksLS 8.1.2. software (Ultra-Violet Products Ltd, US). Images were 
analysed using ImageJ and normalised to β-actin expression. 
 
Statistics 
In order to investigate the individual effects of hypoxic exposure, dietary nitrate and Ppara
-/-
 
and the interactions between these effects, a three-way analysis of variance (ANOVA) was 
performed. The statistical approach used has been described previously (43). Initially, the 
three-way interaction was considered for significance. If there was a significant three-way 
interaction, main effects and two-way interactions were disregarded and a post-hoc Tukey’s 
HSD test performed. Pairwise comparisons of groups between which only one of the 
independent variables differed were considered, and the results recorded. If the three-way 
interaction was not significant but one or more two-way interactions were significant, a post-
hoc Tukey’s HSD test was performed to investigate each two-way interaction. Any main 
effects of variables involved in the significant two-way interaction(s) were not considered, 
while main effects of variables not involved in significant interactions were. In instances 
where no three-way or two-way interactions were significant, the main effects of all three 
independent variables were considered. Main effects combine all four groups in each state of 
one independent variable and make a pairwise comparison between these combinations (e.g. 
all four wild-type vs. all four Ppara
-/-
 groups). All analyses were carried out using R software 
(The R Foundation for Statistical Computing) and P values < 0.05 were considered 
significant. 
Graphs were generated using GraphPad Prism 7 software and follow a colour/pattern scheme 
whereby white indicates normoxia (21% O2), blue hypoxia (10% O2), block colour chloride 
(Cl
-
) and striped nitrate (NO3
-
) treated groups. In addition the wild type groups are separated 
from the Ppara
-/- 
groups. Graphs display results as mean +/- SEM. Statistically significant 
differences between groups are indicated in black (differences between genotypes), blue 
(differences between normoxia and hypoxia) and orange (interactions linked to nitrate 
treatment vs chloride).  





Body mass, blood haemoglobin, and food, water and nitrate intake have been reported 
previously for these mice (35). 
Briefly, food and water intake fell in hypoxic mice in Week 2 (the first week of hypoxic 
exposure). Food intake recovered in hypoxic animals over subsequent weeks, such that it was 
the same in all groups at the end of the study. Water intake recovered more quickly than food 
intake, and was the same in all groups from Week 3 onwards. Inorganic nitrate intake 
calculated from food and water intake and over the course of the study was 153 - 257 
µmol/kg/d in nitrate-treated mice, compared with 18 - 31 µmol/kg/d in chloride-treated mice  
Body mass was the same in all wild-type mice at the start of the study, but Ppara
-/-
 mice were 
6% lighter than wild-types. At the end of the study, Ppara
-/-
 mice were 5% lighter than wild-
types (P < 0.01, PPARα main effect), whilst hypoxic mice were 4% lighter than normoxic 
mice (P < 0.001, hypoxia main effect) and nitrate-treated mice were 3% lighter than chloride-
treated mice (P < 0.05, nitrate main effect). Blood haemoglobin concentration, measured at 
the end of the study, was higher in hypoxic mice than normoxic mice (35). 
Cardiac mitochondrial respiration 
Mass-specific respiration 
Assay 1 was used to measure aspects of FAO and the control exerted by CPT1, with 
respiration rates initially normalised to wet weight of tissue (Fig. 2). Mass-specific respiration 
rates in Ppara
-/- 
mice were 10% (P < 0.01, Fig. 2A), 23% (P < 0.001, Fig. 2B) and 27% lower 
(P < 0.001, Fig. 2C, all PPARα main effect) when limited by proton leak (CPT1L), CPT1 flux 
(CPT1P) and β-oxidation (PalMP), respectively. Hypoxic exposure resulted in 11% lower 
LEAK respiration (P < 0.01, Fig. 2A) and 13% lower OXPHOS supported by β-oxidation (P 
< 0.05, Fig. 2C, both hypoxia main effect). Taken together, these data confirm that PPARα 
supports FAO in the mouse heart, whilst hypoxia suppresses the mass-specific capacity for β-
oxidation. 
Assay 2 was used to measure respiration supported by FAO and substrates for the N-pathway 
via Complex I and the S-pathway via Complex II of the ETS, with respiration rates initially 
normalised to wet weight of tissue (Fig. 3). All respiration rates were lower in Ppara
-/-
 mice 
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compared with wild-types, and in hypoxic mice compared with normoxic mice, whilst dietary 
nitrate supplementation had no effect on mass-specific respiration rates.  
In Ppara
-/-
 mice, LEAK respiration (OctML) and OXPHOS respiration (OctMP) supported by 
malate and octanoyl carnitine were 21% lower (P < 0.001, Fig. 3A) and 45% lower (P < 
0.001, Fig. 3B, both PPARα main effect) than in wild-type mice, underlining the role of 
PPARα in regulating cardiac fatty acid oxidation. Meanwhile, OXPHOS supported by 
pyruvate and malate (PMP) was 16% lower (P < 0.001, Fig. 3C), by glutamate and malate 
(GMP) was 14% lower (P < 0.001, Fig. 3D), by glutamate, malate and succinate (GMSP) was 
9% lower (P < 0.01, Fig. 3E) and by succinate following the addition of rotenone (SP) was 
10% lower (P < 0.01, all PPARα main effect, Fig. 3F). 
In hypoxic mice, OctML and OctMP were 16% (P < 0.001, Fig. 3A) and 17% (P < 0.001, Fig. 
3B) lower than in normoxic mice, whilst PMP was 10% lower (P < 0.01, Fig. 3C), GMP was 
10% lower (P < 0.01, Fig. 3D), GMSP was 10% lower (P < 0.01, Fig. 3E) and SP was 13% 
lower (P < 0.01, Fig. 3F, all hypoxia main effect). 
Together, these data show that both Ppara
 
ablation and hypoxic exposure lower oxidative 
capacity in the mouse heart, with suppression of fatty acid-supported respiration occurring to 
a greater extent than respiration supported by other substrates. This is particularly 
pronounced in the case of Ppara ablation. 
Citrate synthase-specific respiration 
Both hypoxic exposure and Ppara
-/-
 resulted in a general lowering of mass-specific 
respiration rates in mouse heart. This might be attributable to a loss of cardiac mitochondrial 
content or to changes in respiration per mitochondrial unit, and therefore to further probe the 
effects of hypoxia, nitrate and PPARα on mitochondrial respiration, we extracted the contents 
of the oxygraph chambers and measured the activity of citrate synthase (CS) in chamber 
homogenates. CS activity is a putative marker of mitochondrial content (44), and by 
expressing mitochondrial respiration rates relative to CS activity we were able to consider 
respiratory capacities per mitochondrial unit. 
In Assay 1, hypoxia had no effect on any CS-corrected respiration rate (Fig. 4). Dietary 
nitrate supplementation increased CPT1L by 38% (P < 0.01, Fig. 4A), CPT1P by 33% (P < 
0.05, Fig. 4B) and PalMP by 36% (P < 0.01, Fig. 4C, all Tukey’s test of nitrate/PPARα 
interaction) in wild-type but not Ppara
-/-
 mice. Ppara knockout lowered all CS-corrected 
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respiration rates. In normoxic mice, Ppara knockout lowered CPT1L by 25% (P < 0.05, Fig. 
4A), CPT1P by 38% (P < 0.001, Fig. 4B) and PalMP by 38% (P < 0.001, Fig. 4C, all Tukey’s 
test of hypoxia/PPARα interaction). In nitrate-supplemented mice, Ppara knockout lowered 
CPT1L by 23% (P < 0.05, Fig. 4A), CPT1P by 34% (P < 0.001, Fig. 4B) and PalMP by 35% 
(P < 0.001, Fig. 4C, all Tukey’s test of nitrate/PPARα interaction). Taken together, these data 
suggest that Ppara
 
ablation attenuates fatty acid oxidation capacity per mitochondrial unit, 
and that nitrate increases fatty acid oxidation per mitochondrial unit in a PPARα-dependent 
manner. 
In Assay 2, neither nitrate supplementation nor hypoxic treatment affected CS-corrected 
respiration rates (Figure 5). Ppara
 
ablation, however, lowered CS-corrected OctML by 25% 
(P < 0.01, Fig. 5A), OctMP by 27% (P < 0.001, Fig. 5B), PMP by 19% (P < 0.05, Fig. 5C) 
and GMP by 17% (P < 0.05, Fig. 5D, all PPARα main effect). GMSP and SP were unaffected 
by nitrate, hypoxia or genotype (Fig. 5E and 5F). These data further support the notion that 
Ppara ablation attenuates cardiac mitochondrial fatty acid oxidation capacity, in addition to 
any effect on mitochondrial content. 
OXPHOS coupling efficiency 
OXPHOS coupling efficiency, indicating the increase in respiration following addition of 
ADP relative to the resulting respiration rate was calculated for both assays (Supplementary 
Fig. 1). In Assay 1 and Assay 2, OXPHOS coupling efficiency was 19% and 29% lower, 
respectively, in Ppara
-/-
 mice compared with wild-type mice (P < 0.001, PPARα main effect). 
Neither nitrate-supplementation nor hypoxic exposure affected OXPHOS coupling 
efficiency. This data suggests that whilst PPARα enhanced fatty acid-supported respiration in 
both LEAK and OXPHOS states, the effect on the OXPHOS state was proportionally greater. 
Substrate control ratios 
To further investigate the effects of nitrate-supplementation, hypoxic-exposure and PPARα 
on cardiac mitochondrial respiration, and the interactions between these three factors, we 
used substrate control ratios to interrogate control points and substrate-led pathways (Fig. 6). 
Firstly, to understand the effect of these factors on the activity of CPT1 (an enzyme 
responsible for the entry of long chain fatty acid substrates into mitochondria via the addition 
of carnitine) we expressed CPT1P relative to PalMP (FCRCPT1, Fig. 6A). Here we found that 
the substrate control ratio was unaffected by any factor, indicating that whilst in Ppara
-/-
 mice 
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and hypoxic mice OXPHOS supported by CPT1 substrates and β-oxidation are suppressed, 
the effects on these two respiration rates are proportionally similar. 
Next, we sought to understand the contribution of three substrate-led pathways to total 
OXPHOS capacity, expressing OXPHOS supported by a) the F-pathway via β-oxidation 
(OctMP), b) the N-pathway via complex I (GMP) and c) the S-pathway via complex II (SP), 
relative to maximal OXPHOS (GMSP).  
In wild-type, but not Ppara
-/-
 mice, exposure to hypoxia lowered OXPHOS respiration 
through the F-pathway relative to maximal OXPHOS (FCRF) by 32% (P < 0.001, Tukey’s 
test of hypoxia/PPARα interaction, Fig. 6B). Similarly, this was 41% lower in normoxic 
Ppara
-/-
 mice compared with wild-type mice. This suggests that hypoxic exposure lowers 
fatty acid oxidation, relative to maximal OXPHOS, in a PPARα-dependent manner. 
OXPHOS supported by the N-pathway via complex I, relative to maximal OXPHOS (FCRN), 
was 7% lower in Ppara
-/-
 mice compared with wild-type mice (P < 0.001, PPARα main 
effect, Supplementary Fig. 2A) but was unaffected by hypoxic exposure or nitrate 
supplementation. Meanwhile, OXPHOS supported by the S-pathway via complex II (FCRS), 
was unaffected by Ppara ablation or hypoxia, but was 2% higher in nitrate-supplemented 
mice (P < 0.05, nitrate main effect, Supplementary Fig. 2B). 
Finally, we expressed octanoyl carnitine-supported OXPHOS (OctMP) relative to pyruvate-
supported OXPHOS (PMP) in order to indicate the relative capacity for FAO compared with 
pyruvate-linked respiration through the N-pathway (FCROct/P, Fig. 6C). The relative capacity 
for FAO was decreased by hypoxia in chloride-supplemented wild-type mice by 18% (P < 
0.001, Tukey’s test of nitrate/hypoxic/PPARα interaction) but not in nitrate-supplemented 
wild-type mice nor in either group of hypoxic Ppara
-/-
 mice. Dietary nitrate reversed this 
effect in hypoxic wild-type mice, increasing the relative capacity for FAO by 17% (P < 0.05, 
Tukey’s test of nitrate/hypoxia/PPARα). Again, no effect was seen in Ppara
-/-
 mice. The 
relative capacity for FAO was, however, lower in Ppara
-/-
 mice (P < 0.001, Tukey’s test of 
nitrate/hypoxia/PPARα interaction). These data therefore demonstrate that in mouse heart (i) 
Ppara ablation induces a substrate switch away from fatty acids, (ii) exposure to hypoxia 
induces a substrate switch away from fatty acids acting via decreased PPARα activity, and 
(iii) dietary nitrate prevents the hypoxia-induced substrate switch in a PPARα-dependent 
manner. 
  




Hypoxic exposure resulted in 32% lower citrate synthase activities in wild-type mouse hearts 
compared with those of their normoxic counterparts (P < 0.05, Tukey’s test of 
hypoxia/PPARα interaction) but did not affect CS activity in Ppara
-/-
 mice (Fig. 7A). 
Nitrate-supplemented wild-type mice had 33% higher activities of the β-oxidation enzyme 
HADH in heart (P < 0.01), whilst no effect was seen in Ppara
-/-
 mice (Fig. 7B). Moreover, in 
Ppara
-/-
 mice supplemented with nitrate, but not by chloride, HADH activity was 35% lower 
than in wild-type counterparts (P < 0.01, Tukey’s test of nitrate/PPARα interaction). This 
suggests that dietary nitrate increases HADH activity in cardiac tissue via a PPARα-
dependent mechanism. 
Hexokinase activity was 33% higher in hypoxic groups, relative to normoxic counterparts (P 
< 0.001, hypoxia main effect), with no significant effect on hexokinase activity resulting 
from nitrate supplementation or genotype (Fig. 7C). Hypoxia also increased LDH activity by 
71% in wild-type, but not Ppara
-/-
 mice (P < 0.001, Tukey’s test of hypoxia/PPARα 
interaction, Fig. 7D). Hypoxia was also permissive of a PPARα effect, since under hypoxic 
but not normoxic conditions Ppara ablation resulted in 50% lower LDH activities (P < 0.001, 
Tukey’s test of hypoxia/PPARα interaction). Dietary nitrate did not affect the activity of 
either hexokinase or LDH. Thus, hypoxia increased hexokinase activity in a manner that was 
independent of dietary nitrate and PPARα, but increased LDH in a manner that was 
dependent upon PPARα. 
Pyruvate dehydrogenase levels and phosphorylation 
To examine the regulation of pyruvate oxidation, total and phosphorylated PDH levels were 
measured in cardiac homogenates by immunoblotting. There was no specific effect of 
hypoxia on total PDH levels (Fig 8A), although total levels were higher in hypoxic nitrate-
supplemented wild-type mice compared with their normoxic counterparts (P < 0.05, Tukey’s 
test of hypoxia/nitrate/PPARα interaction). Hypoxia increased phosphorylation of PDH at 
serine residues 232, 293 and 300 in wild-type mice, and this was prevented by nitrate 
supplementation (P < 0.01, Tukey’s test of hypoxia/nitrate/PPARα interaction, Fig 8B-D). 
There was no clear effect of hypoxia on phosphorylation of any serine residue in Ppara
-/-
 
mice. At serine 232, nitrate supplementation appeared to enhance phosphorylation in hypoxic 
Ppara
-/-
 mice (P < 0.05, Tukey’s test of hypoxia/nitrate/PPARα interaction, Fig 8B). Overall, 
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these data suggest hypoxia increases PDH inhibition by phosphorylation in a PPARα-
dependent manner, whilst nitrate prevents this.   




We have previously demonstrated that a moderate dose of dietary nitrate protects 
mitochondrial respiratory function, FAO and energetics in the hypoxic rat heart (33), and 
enhances skeletal muscle FAO capacity through a mechanism dependent upon activation of 
PPARα (34). Decreased PPARα transcriptional activity appears to be a key aspect of the 
cardiac metabolic response to hypoxia (8, 9), so here we sought to understand whether 
PPARα plays a role in mediating the protective effect of nitrate in the hypoxic heart. 
We found that hypoxic exposure was associated with the suppression of mass-specific 
respiratory capacity and citrate synthase activity in mouse heart, with no protective effect of 
nitrate. Mass-specific respiration was also lower in Ppara
-/-
 mice compared with wild-type 
mice. Hypoxia increased phosphorylation of PDH in wild-type mice, and also increased the 
capacity for glycolysis with increased hexokinase activity in all mice and increased LDH 
activity in wild-type mice. In addition to the general suppression of oxidative capacity, 
hypoxia resulted in a particular downregulation of FAO capacity in wild-type mice. This was 
reversed by nitrate treatment, an effect not apparent in Ppara
-/-
 mice. Similarly, nitrate 
increased activity of HADH in wild-type mice, but not Ppara
-/-
 mice. 
Strengths of this study include the use of high-resolution measurements of oxygen flux to 
consider multiple aspects of FAO capacity with both CPT1-dependent and independent 
substrates. Our inclusion of both mass-specific and mitochondrial-specific FAO capacity 
measurements, as well as FAO in proportion to maximal OXPHOS capacity is also a 
strength. It should be noted, however, that all measurements were carried out under 
conditions where oxygen and substrates were saturating, and whilst our data indicate 
alterations in respiratory capacity there may be further, subtle differences in mitochondrial 
respiration in vivo at physiological oxygen and substrate concentrations that we have not 
measured here. The use of permeabilised fibres, rather than isolated mitochondria, allowed us 
to measure respiration in the entire population of cardiac mitochondria, albeit without 
allowing us to distinguish between effects on the interfibrillar and subsarcolemmal 
populations of mitochondria (45). A further strength of this study was the statistical approach, 
which, whilst complex, allowed us to directly address the key hypothesis that nitrate exerts 
effects in hypoxia acting through PPARα. The three-way ANOVA approach allowed us to 
test the interaction between these three factors, and represented a conservative approach, 
eliminating the need for multiple comparisons and strengthening the conclusions of this 
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study. This approach, however, does increase the chance of type 2 errors and is not suitable 
for testing differences between just two of the groups, e.g. the effect of hypoxia on wild-type 
(non-nitrate-supplemented) mice, for which a more targeted study design would be more 
appropriate. 
The use of mice, rather than rats, is both a strength and a weakness of this study. The Ppara
-/-
 
mouse has been studied extensively, particularly in relation to the role of PPARα in 
regulating FAO in various tissues, and was a valuable component of this study. Mice, 
however, differ from rats and humans, in their NO production rates (46) and concentrations 
of circulating nitrate/nitrite levels (47).  Moreover, we only used male mice in this study, 
which may be a limitation since, for example, gender dimorphic differences in the anti-
platelet response to nitrate supplementation have been observed in humans (48). As with our 
previous studies, we were able to precisely control nitrate intake using a standardised quality-
controlled diet and deionised water (23, 33-35, 49, 50). Whilst the anorexic effects in the 
early stages of hypoxic exposure may have confounded our findings, the long duration of the 
hypoxic exposure proved to be a strength since water intake and therefore nitrate intake 
stabilised in hypoxic mice by week 2, matching that of their normoxic counterparts for the 
remainder of the study.  
Unlike our previous findings in rat heart (33), however, we saw no protective effect of nitrate 
supplementation on mass-specific oxidative phosphorylation. This could be due to species 
differences, indeed 17 months of NaNO3 supplementation at 1 mM did not alter plasma 
nitrate concentration in mice (51), whilst 0.7 mM NaNO3 increased circulating nitrate in rats 
(33). It should be noted, however, that both the duration (4 weeks) and degree of hypoxia 
(10% O2) were more severe in this study than in our previous work (2 weeks at 13% O2), and 
this may have limited the effectiveness of nitrate supplementation. Of note, the increased 
activity of LDH is an established hypoxia response in heart (52) and this was seen in both 
chloride-supplemented and nitrate-supplemented mice, perhaps suggesting that nitrate 
supplementation didn’t fully restore O2 delivery to these hearts.  
The general suppression of mass-specific respiratory capacity, particularly in the context of 
more prolonged and severe hypoxia, might be explained by a loss of mitochondrial content in 
these hearts. Indeed we saw that hypoxia lowered CS activity in the hearts of wild-type mice 
in this study, whilst there was no such change in CS in our previous study which employed a 
milder hypoxia protocol (33). In skeletal muscle, the suppression of CS is dependent on both 
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duration and degree of hypoxia (53). CS activity is a putative marker of mitochondrial 
density, correlating with mitochondrial volume in the skeletal muscle of healthy, young adult 
humans (44) although whether this correlation holds in the mouse heart under all conditions 
described here is unknown.  
In addition to the general effect of hypoxia on mass-specific respiration, a particular 
suppression of FAO was seen. This was indicated by a fall in CS-corrected respiration rates 
for fatty acid substrates, and also by substrate control ratios expressing FAO as a proportion 
of maximal OXPHOS or in relation to pyruvate-supported OXPHOS. This effect of hypoxia 
was seen in the hearts of wild-type but not Ppara
-/-
 mice, indicating that the hypoxic 
suppression of FAO is primarily driven by decreased PPARα activity, as suggested 
previously (8). There was no specific effect on CPT1-supported FAO (with palmitoyl-CoA 
plus malate) compared with CPT1-independent respiration (with palmitoyl carnitine plus 
malate), indicating that whilst CPT1 activity may be downregulated there are also effects of a 
similar magnitude downstream, probably on β-oxidation capacity, although in agreement 
with our previous work (9) HADH activity was unaltered by hypoxia. Whilst the severity of 
the hypoxic stimulus used here may have prevented any restorative effect of nitrate on mass-
specific respiration, nitrate did prevent the particular suppression of FAO, but only in wild-
type mice, suggesting that PPARα is necessary for these nitrate-mediated effects to occur. 




In addition to the effect of hypoxia, mass-specific respiratory capacity was lower in the hearts 
of Ppara
-/-
 mice than those of wild-type mice, and as might be expected this was most 
pronounced for respiration rates supported by fatty acid substrates, although a suppression of 
respiration supported by substrates for the N-pathway via complex I (pyruvate, glutamate and 
malate) and the S-pathway via complex II (succinate) was also seen. When corrected for CS 
activity, respiration supported by fatty acid substrates remained lower in Ppara
-/-
 mice 
compared with wild-type mice, underlining its importance in regulating cardiac FAO, but of 
note respiration supported by N-pathway substrates was also was lower in Ppara
-/-
 mice. 
Unlike in wild-type mice, there was no effect of nitrate supplementation on FAO capacity or 
HADH activity in Ppara
-/-
 mice, demonstrating that in line with our initial hypothesis, 
PPARα is an essential mediator of the effects of nitrate on cardiac metabolism in hypoxia. 
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Activities of hexokinase and LDH were increased following hypoxia as did PDH 
phosphorylation, all suggesting an upregulation of glycolytic capacity. Whilst the increase in 
hexokinase activity was not dependent on PPARα, occurring in mice of both genotypes, the 
increase in LDH dehydrogenase activity only occurred in wild-type mice, suggesting an 
unexpected influence of PPARα on Ldh expression. PPARβ/δ has been shown to decrease the 
expression ratio of Ldha/Ldhb in skeletal muscle (54), but we are not aware of any previously 
reported effects of PPARα. While Ldhb encodes a LDH isoform that encourages the 
conversion of lactate to pyruvate, the protein product of Ldha favours the conversion of 
pyruvate to lactate. It is plausible therefore, that PPARα ablation is compensated by an 
increase in PPARβ/δ, which prevents a hypoxia-induced increase in Ldha/Ldhb, though this 
would have to be confirmed with gene expression studies. Alternatively, PPARα is known to 
increase pyruvate dehydrogenase kinase (PDK)4 activity, leading to an attenuation of PDH 
activity. This could increase pyruvate concentration, which may feed forward to increase 
LDH activity. Indeed, whilst hypoxia increased PDH phosphorylation in wild-type mice, 
potentially via HIF-dependent upregulation of PDK1 (6, 7), this effect was blunted in Ppara
-/-
 
mice. Taken together, these data implicate a switch away from oxidative metabolism towards 
glycolysis in the hypoxic mouse heart. 
Our data therefore suggest that PPARα plays a key role in regulating the process of metabolic 
remodelling that occurs in the hypoxic heart, and is essential for the effects of dietary nitrate 
in preserving oxidative metabolism. This is in contrast to our previous findings in skeletal 
muscle where the metabolic response to hypoxia +/- nitrate was found to be the same in wild-
type mice and Ppara
-/-
 mice (35). The difference between the two tissues, and greater 
dependence on PPARα in heart, might be explained by the higher expression of PPARα in 
cardiac muscle compared with skeletal muscle (3). Nitrate supplementation did exert effects 
in hypoxic skeletal muscle, but this may have been due to effects via PPARβ/δ (36), or 
through haemodynamic changes that alter blood flow and O2 delivery (20). Our data do not 
definitively address whether nitrate exerts its effects by altering blood flow and therefore O2 
delivery or through direct effects on tissue metabolism. Although PPARα is an essential 
effector in this response, its transcriptional activity may simply be modified by HIF-
signalling in response to changes in tissue oxygenation in order to ensure that oxidative 
metabolism is supported only when sufficient oxygen is available.  Arguing against this is our 
finding here that hexokinase and LDH activity were increased by hypoxia in both chloride-
supplemented and nitrate-supplemented hearts, indicating that whilst the dose of nitrate 
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employed here did modulate FAO, it was not sufficient to ameliorate the fall in oxygenation 
through improved blood flow. Moreover, our previous work in cultured myotubes indicated 
that nitrate enhanced PPARα activity without changes in oxygenation (34), and it would be 
interesting to replicate this in cardiomyocytes. It seems likely that nitrate exerts 
complementary but separate effects on blood flow and metabolism, ensuring that tissue O2 
supply and demand are matched. 
Our work has implications for a number of conditions where cardiac and skeletal muscle 
metabolism is pathologically altered, particularly where derangements in NO production or 
availability have been implicated. For instance, endothelial NOS (eNOS) knockout mice 
develop a metabolic syndrome-like phenotype, including obesity and insulin resistance, yet 
features of the pathology were reversed following nitrate supplementation (55). It has been 
suggested that nitrate supplementation may be of benefit to patients with heart failure with 
reduced ejection fraction (HFrEF) in whom eNOS activity is impaired (56). A recent study 
demonstrated improvements in NO bioavailability and muscle power following nitrate 
supplementation in 9 patients with HFrEF (56) and it would be interesting to see if this was 
associated with changes in tissue metabolism in addition to improvements in blood flow. The 
failing heart itself is energy-starved (57) and characterised by a downregulation of FAO (1, 
57), which may improve the efficiency of O2 utilisation. It was shown, however, that 
oxygenation was not impaired in the non-ischaemic failing myocardium (58), and thus 
therapeutic strategies that enhance oxidative metabolism, including perhaps nitrate 
supplementation, may be of benefit to these patients. 
In conclusion, hypoxia suppresses oxidative metabolism in the heart and enhances glycolytic 
capacity. In addition, there is a particular suppression of FAO in the hypoxic heart, which is 
mediated through decreased PPARα transcriptional activity, and can be reversed by 
supplementation with dietary nitrate in a PPARα-dependent manner.   




This work was supported by the Biotechnology and Biological Sciences Research Council, 
UK [grant number: BB/F016581/1] and the Research Councils UK [grant number: 
EP/E500552/1]. The authors acknowledge the support of Professor Kieran Clarke (University 
of Oxford) and Professor Martin Feelisch (University of Southampton). 
 
Author Contributions 
JAH, KAO, SDRH and AJM designed research; JAH, KAO, ADC, RTL, ASS, NEKP and JD 
performed research; JAH, KAO, ADC, RTL, NEKP, MF and AJM analysed data; JAH, 
KAO, NEKP and AJM wrote the paper and all authors approved submission. 
 
  




1. Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S., and Stanley, W. C. 
(2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90, 207-
258 
2. Essop, M. F. (2007) Cardiac metabolic adaptations in response to chronic hypoxia. J 
Physiol 584, 715-726 
3. Rakhshandehroo, M., Knoch, B., Muller, M., and Kersten, S. (2010) Peroxisome 
proliferator-activated receptor alpha target genes. PPAR Res 2010 
4. Wu, R., Chang, H. C., Khechaduri, A., Chawla, K., Tran, M., Chai, X., Wagg, C., 
Ghanefar, M., Jiang, X., Bayeva, M., Gonzalez, F., Lopaschuk, G., and Ardehali, H. 
(2014) Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy. J 
Clin Invest 124, 4795-4806 
5. Belanger, A. J., Luo, Z., Vincent, K. A., Akita, G. Y., Cheng, S. H., Gregory, R. J., 
and Jiang, C. (2007) Hypoxia-inducible factor 1 mediates hypoxia-induced 
cardiomyocyte lipid accumulation by reducing the DNA binding activity of 
peroxisome proliferator-activated receptor alpha/retinoid X receptor. Biochem 
Biophys Res Commun 364, 567-572 
6. Kim, J. W., Tchernyshyov, I., Semenza, G. L., and Dang, C. V. (2006) HIF-1-
mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required 
for cellular adaptation to hypoxia. Cell Metab 3, 177-185 
7. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., and Denko, N. C. (2006) HIF-1 
mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen 
consumption. Cell Metab 3, 187-197 
8. Cole, M. A., Abd Jamil, A. H., Heather, L. C., Murray, A. J., Sutton, E. R., Slingo, 
M., Sebag-Montefiore, L., Tan, S. C., Aksentijevic, D., Gildea, O. S., Stuckey, D. J., 
Yeoh, K. K., Carr, C. A., Evans, R. D., Aasum, E., Schofield, C. J., Ratcliffe, P. J., 
Neubauer, S., Robbins, P. A., and Clarke, K. (2016) On the pivotal role of PPARalpha 
in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury. 
FASEB J 30, 2684-2697 
9. Horscroft, J. A., Burgess, S. L., Hu, Y., and Murray, A. J. (2015) Altered Oxygen 
Utilisation in Rat Left Ventricle and Soleus after 14 Days, but Not 2 Days, of 
Environmental Hypoxia. PLoS One 10, e0138564 
10. Holloway, C. J., Montgomery, H. E., Murray, A. J., Cochlin, L. E., Codreanu, I., 
Hopwood, N., Johnson, A. W., Rider, O. J., Levett, D. Z., Tyler, D. J., Francis, J. M., 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
27 
 
Neubauer, S., Grocott, M. P., Clarke, K., and Caudwell Xtreme Everest Research, G. 
(2011) Cardiac response to hypobaric hypoxia: persistent changes in cardiac mass, 
function, and energy metabolism after a trek to Mt. Everest Base Camp. FASEB J 25, 
792-796 
11. Larsen, F. J., Schiffer, T. A., Borniquel, S., Sahlin, K., Ekblom, B., Lundberg, J. O., 
and Weitzberg, E. (2011) Dietary inorganic nitrate improves mitochondrial efficiency 
in humans. Cell Metab 13, 149-159 
12. Duncan, C., Dougall, H., Johnston, P., Green, S., Brogan, R., Leifert, C., Smith, L., 
Golden, M., and Benjamin, N. (1995) Chemical generation of nitric oxide in the 
mouth from the enterosalivary circulation of dietary nitrate. Nat Med 1, 546-551 
13. Benjamin, N., O'Driscoll, F., Dougall, H., Duncan, C., Smith, L., Golden, M., and 
McKenzie, H. (1994) Stomach NO synthesis. Nature 368, 502 
14. Shiva, S., Wang, X., Ringwood, L. A., Xu, X., Yuditskaya, S., Annavajjhala, V., 
Miyajima, H., Hogg, N., Harris, Z. L., and Gladwin, M. T. (2006) Ceruloplasmin is a 
NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat 
Chem Biol 2, 486-493 
15. Gardner, P. R. (2005) Nitric oxide dioxygenase function and mechanism of 
flavohemoglobin, hemoglobin, myoglobin and their associated reductases. J Inorg 
Biochem 99, 247-266 
16. Millar, T. M., Stevens, C. R., Benjamin, N., Eisenthal, R., Harrison, R., and Blake, D. 
R. (1998) Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to 
nitric oxide under hypoxic conditions. FEBS Lett 427, 225-228 
17. Cosby, K., Partovi, K. S., Crawford, J. H., Patel, R. P., Reiter, C. D., Martyr, S., 
Yang, B. K., Waclawiw, M. A., Zalos, G., Xu, X., Huang, K. T., Shields, H., Kim-
Shapiro, D. B., Schechter, A. N., Cannon, R. O., 3rd, and Gladwin, M. T. (2003) 
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human 
circulation. Nat Med 9, 1498-1505 
18. Shiva, S., Huang, Z., Grubina, R., Sun, J., Ringwood, L. A., MacArthur, P. H., Xu, 
X., Murphy, E., Darley-Usmar, V. M., and Gladwin, M. T. (2007) Deoxymyoglobin is 
a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. 
Circ Res 100, 654-661 
19. Gautier, C., van Faassen, E., Mikula, I., Martasek, P., and Slama-Schwok, A. (2006) 
Endothelial nitric oxide synthase reduces nitrite anions to NO under anoxia. Biochem 
Biophys Res Commun 341, 816-821 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
28 
 
20. Palmer, R. M., Ferrige, A. G., and Moncada, S. (1987) Nitric oxide release accounts 
for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-
526 
21. Mittal, C. K., and Murad, F. (1977) Properties and oxidative regulation of guanylate 
cyclase. J Cyclic Nucleotide Res 3, 381-391 
22. Taylor, D. A., Bowman, B. F., and Stull, J. T. (1989) Cytoplasmic Ca2+ is a primary 
determinant for myosin phosphorylation in smooth muscle cells. J Biol Chem 264, 
6207-6213 
23. Ashmore, T., Fernandez, B. O., Evans, C. E., Huang, Y., Branco-Price, C., Griffin, J. 
L., Johnson, R. S., Feelisch, M., and Murray, A. J. (2015) Suppression of 
erythropoiesis by dietary nitrate. FASEB J 29, 1102-1112 
24. Martin, D. S., Ince, C., Goedhart, P., Levett, D. Z., Grocott, M. P., and Caudwell 
Xtreme Everest Research, G. (2009) Abnormal blood flow in the sublingual 
microcirculation at high altitude. Eur J Appl Physiol 106, 473-478 
25. Erzurum, S. C., Ghosh, S., Janocha, A. J., Xu, W., Bauer, S., Bryan, N. S., Tejero, J., 
Hemann, C., Hille, R., Stuehr, D. J., Feelisch, M., and Beall, C. M. (2007) Higher 
blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. 
Proc Natl Acad Sci U S A 104, 17593-17598 
26. Beall, C. M., Cavalleri, G. L., Deng, L., Elston, R. C., Gao, Y., Knight, J., Li, C., Li, 
J. C., Liang, Y., McCormack, M., Montgomery, H. E., Pan, H., Robbins, P. A., 
Shianna, K. V., Tam, S. C., Tsering, N., Veeramah, K. R., Wang, W., Wangdui, P., 
Weale, M. E., Xu, Y., Xu, Z., Yang, L., Zaman, M. J., Zeng, C., Zhang, L., Zhang, X., 
Zhaxi, P., and Zheng, Y. T. (2010) Natural selection on EPAS1 (HIF2alpha) 
associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad 
Sci U S A 107, 11459-11464 
27. Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., 
Valerio, A., Cantoni, O., Clementi, E., Moncada, S., and Carruba, M. O. (2005) 
Calorie restriction promotes mitochondrial biogenesis by inducing the expression of 
eNOS. Science 310, 314-317 
28. Brown, G. C., and Cooper, C. E. (1994) Nanomolar concentrations of nitric oxide 
reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome 
oxidase. FEBS Lett 356, 295-298 
29. Huie, R. E., and Padmaja, S. (1993) The reaction of no with superoxide. Free Radic 
Res Commun 18, 195-199 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
29 
 
30. Radi, R. (2013) Peroxynitrite, a stealthy biological oxidant. J Biol Chem 288, 26464-
26472 
31. Clementi, E., Brown, G. C., Feelisch, M., and Moncada, S. (1998) Persistent 
inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of 
mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S 
A 95, 7631-7636 
32. Larsen, F. J., Weitzberg, E., Lundberg, J. O., and Ekblom, B. (2010) Dietary nitrate 
reduces maximal oxygen consumption while maintaining work performance in 
maximal exercise. Free Radic Biol Med 48, 342-347 
33. Ashmore, T., Fernandez, B. O., Branco-Price, C., West, J. A., Cowburn, A. S., 
Heather, L. C., Griffin, J. L., Johnson, R. S., Feelisch, M., and Murray, A. J. (2014) 
Dietary nitrate increases arginine availability and protects mitochondrial complex I 
and energetics in the hypoxic rat heart. J Physiol 592, 4715-4731 
34. Ashmore, T., Roberts, L. D., Morash, A. J., Kotwica, A. O., Finnerty, J., West, J. A., 
Murfitt, S. A., Fernandez, B. O., Branco, C., Cowburn, A. S., Clarke, K., Johnson, R. 
S., Feelisch, M., Griffin, J. L., and Murray, A. J. (2015) Nitrate enhances skeletal 
muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism. 
BMC Biol 13, 110 
35. O'Brien, K. A., Horscroft, J. A., Devaux, J., Lindsay, R. T., Steel, A. S., Clark, A. D., 
Philp, A., Harridge, S. D. R., and Murray, A. J. (2018) PPARalpha-independent 
effects of nitrate supplementation on skeletal muscle metabolism in hypoxia. Biochim 
Biophys Acta Mol Basis Dis  
36. Muoio, D. M., MacLean, P. S., Lang, D. B., Li, S., Houmard, J. A., Way, J. M., 
Winegar, D. A., Corton, J. C., Dohm, G. L., and Kraus, W. E. (2002) Fatty acid 
homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome 
proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for 
compensatory regulation by PPAR delta. J Biol Chem 277, 26089-26097 
37. Pesta, D., and Gnaiger, E. (2012) High-resolution respirometry: OXPHOS protocols 
for human cells and permeabilized fibers from small biopsies of human muscle. 
Methods Mol Biol 810, 25-58 
38. Heather, L. C., Cole, M. A., Tan, J. J., Ambrose, L. J., Pope, S., Abd-Jamil, A. H., 
Carter, E. E., Dodd, M. S., Yeoh, K. K., Schofield, C. J., and Clarke, K. (2012) 
Metabolic adaptation to chronic hypoxia in cardiac mitochondria. Basic Res Cardiol 
107, 268 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
30 
 
39. Horscroft, J. A., Kotwica, A. O., Laner, V., West, J. A., Hennis, P. J., Levett, D. Z. 
H., Howard, D. J., Fernandez, B. O., Burgess, S. L., Ament, Z., Gilbert-Kawai, E. T., 
Vercueil, A., Landis, B. D., Mitchell, K., Mythen, M. G., Branco, C., Johnson, R. S., 
Feelisch, M., Montgomery, H. E., Griffin, J. L., Grocott, M. P. W., Gnaiger, E., 
Martin, D. S., and Murray, A. J. (2017) Metabolic basis to Sherpa altitude adaptation. 
Proc Natl Acad Sci U S A 114, 6382-6387 
40. Houle-Leroy, P., Garland, T., Jr., Swallow, J. G., and Guderley, H. (2000) Effects of 
voluntary activity and genetic selection on muscle metabolic capacities in house mice 
Mus domesticus. J Appl Physiol (1985) 89, 1608-1616 
41. McClelland, G. B., Dalziel, A. C., Fragoso, N. M., and Moyes, C. D. (2005) Muscle 
remodeling in relation to blood supply: implications for seasonal changes in 
mitochondrial enzymes. J Exp Biol 208, 515-522 
42. Levett, D. Z., Radford, E. J., Menassa, D. A., Graber, E. F., Morash, A. J., Hoppeler, 
H., Clarke, K., Martin, D. S., Ferguson-Smith, A. C., Montgomery, H. E., Grocott, M. 
P., Murray, A. J., and Caudwell Xtreme Everest Research Group. (2012) 
Acclimatization of skeletal muscle mitochondria to high-altitude hypoxia during an 
ascent of Everest. FASEB J 26, 1431-1441 
43. Cohen, B. H. (2013) Explaining psychological statistics, Wiley, Hoboken, New Jersey 
44. Larsen, S., Nielsen, J., Hansen, C. N., Nielsen, L. B., Wibrand, F., Stride, N., 
Schroder, H. D., Boushel, R., Helge, J. W., Dela, F., and Hey-Mogensen, M. (2012) 
Biomarkers of mitochondrial content in skeletal muscle of healthy young human 
subjects. J Physiol 590, 3349-3360 
45. Palmer, J. W., Tandler, B., and Hoppel, C. L. (1985) Biochemical differences between 
subsarcolemmal and interfibrillar mitochondria from rat cardiac muscle: effects of 
procedural manipulations. Arch Biochem Biophys 236, 691-702 
46. Siervo, M., Stephan, B. C., Feelisch, M., and Bluck, L. J. (2011) Measurement of in 
vivo nitric oxide synthesis in humans using stable isotopic methods: a systematic 
review. Free Radic Biol Med 51, 795-804 
47. Pannala, A. S., Mani, A. R., Spencer, J. P., Skinner, V., Bruckdorfer, K. R., Moore, K. 
P., and Rice-Evans, C. A. (2003) The effect of dietary nitrate on salivary, plasma, and 
urinary nitrate metabolism in humans. Free Radic Biol Med 34, 576-584 
48. Velmurugan, S., Kapil, V., Ghosh, S. M., Davies, S., McKnight, A., Aboud, Z., 
Khambata, R. S., Webb, A. J., Poole, A., and Ahluwalia, A. (2013) Antiplatelet 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
31 
 
effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of 
sex. Free Radic Biol Med 65, 1521-1532 
49. Roberts, L. D., Ashmore, T., Kotwica, A. O., Murfitt, S. A., Fernandez, B. O., 
Feelisch, M., Murray, A. J., and Griffin, J. L. (2015) Inorganic nitrate promotes the 
browning of white adipose tissue through the nitrate-nitrite-nitric oxide pathway. 
Diabetes 64, 471-484 
50. Roberts, L. D., Ashmore, T., McNally, B. D., Murfitt, S. A., Fernandez, B. O., 
Feelisch, M., Lindsay, R., Siervo, M., Williams, E. A., Murray, A. J., and Griffin, J. 
L. (2017) Inorganic Nitrate Mimics Exercise-Stimulated Muscular Fiber-Type 
Switching and Myokine and gamma-Aminobutyric Acid Release. Diabetes 66, 674-
688 
51. Hezel, M. P., Liu, M., Schiffer, T. A., Larsen, F. J., Checa, A., Wheelock, C. E., 
Carlstrom, M., Lundberg, J. O., and Weitzberg, E. (2015) Effects of long-term dietary 
nitrate supplementation in mice. Redox Biol 5, 234-242 
52. Selmeci, L., Farkas, A., Posch, E., Szelenyi, I., and Sos, J. (1967) The effect of 
hypoxia on the lactic dehydrogenase (LDH) activity of serum and heart muscle of 
rats. Life Sci 6, 649-653 
53. Horscroft, J. A., and Murray, A. J. (2014) Skeletal muscle energy metabolism in 
environmental hypoxia: climbing towards consensus. Extrem Physiol Med 3, 19 
54. Gan, Z., Burkart-Hartman, E. M., Han, D.-H., Finck, B., Leone, T. C., Smith, E. Y., 
Ayala, J. E., Holloszy, J., and Kelly, D. P. (2011) The nuclear receptor PPARβ/δ 
programs muscle glucose metabolism in cooperation with AMPK and MEF2. Genes 
& development 25, 2619-2630 
55. Carlstrom, M., Larsen, F. J., Nystrom, T., Hezel, M., Borniquel, S., Weitzberg, E., 
and Lundberg, J. O. (2010) Dietary inorganic nitrate reverses features of metabolic 
syndrome in endothelial nitric oxide synthase-deficient mice. Proc Natl Acad Sci U S 
A 107, 17716-17720 
56. Mulkareddy, V., Racette, S. B., Coggan, A. R., and Peterson, L. R. (2018) Dietary 
nitrate's effects on exercise performance in heart failure with reduced ejection fraction 
(HFrEF). Biochim Biophys Acta Mol Basis Dis  
57. Neubauer, S. (2007) The failing heart--an engine out of fuel. N Engl J Med 356, 1140-
1151 
58. Dass, S., Holloway, C. J., Cochlin, L. E., Rider, O. J., Mahmod, M., Robson, M., 
Sever, E., Clarke, K., Watkins, H., Ashrafian, H., Karamitsos, T. D., and Neubauer, S. 
Horscroft et al. Nitrate, hypoxia and cardiac energy metabolism 
32 
 
(2015) No Evidence of Myocardial Oxygen Deprivation in Nonischemic Heart 
Failure. Circ Heart Fail 8, 1088-1093 
  
  




Figure 1 Study design. Each stage of the study took place within the ages shown ± 4 d, 
and the length of each stage was identical for each mouse. The left-hand 
section represents wild-type (Ppara
+/+
) mice, whilst the right-hand section 
represents Ppara
-/-
 mice. The number in brackets indicates the number of mice 
per group. Chloride, 0.7 mM NaCl in distilled water ad libitum; Nitrate, 0.7 
mM NaNO3 in distilled water ad libitum; Normoxia, 21% atmospheric O2; 
Hypoxia, 10% atmospheric O2. Background patterns reflect those used in 
figures throughout this manuscript. 
Figure 2 Mitochondrial respiratory function from Assay 1 normalised to mass. A) 
Malate and palmitoyl CoA stimulated LEAK respiration (CPT1L); B) CPT1-
limited OXPHOS (CPT1P); C) OXPHOS supported by the F-pathway via β-





mice following normoxia (white bars, 21% O2) or 
hypoxia (blue bars, 10% O2), and chloride (open bars, 0.7 mM NaCl) or nitrate 
(striped bars, 0.7 mM NaNO3) supplementation. Error bars indicate SEM. * = 
main effect. Blue symbols (*) = hypoxia effect; black symbols (*) = PPARα 
effect. 1 symbol (*) = P < 0.05; 2 symbols (**) = P < 0.01; 3 symbols (***) = 




) denote significance of a test of a 
combination of groups (i.e. main effects or two-way interactions) as described 
in the text. n = 8-11 per group. 
Figure 3 Mitochondrial respiratory function from Assay 2 normalised to mass. A) 
Malate and octanoyl carnitine stimulated LEAK respiration (OctML); B) 
OXPHOS supported by the F-pathway via β-oxidation (OctMP); C) OXPHOS 
supported by pyruvate and malate through the N-pathway via complex I 
(PMP); D) OXPHOS supported by glutamate and malate through the N-
pathway via complex I (GMP); E) OXPHOS supported by glutamate, malate 
and succinate through the NS-pathway via complexes I and II (GMSP); F) by 
succinate following the addition of rotenone (SP) in permeabilised cardiac 




mice following normoxia 
(white bars, 21% O2) or hypoxia (blue bars, 10% O2), and chloride (open bars, 
0.7 mM NaCl) or nitrate (striped bars, 0.7 mM NaNO3) supplementation. 
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Error bars indicate SEM. * = main effect. Blue symbols (*) = hypoxia effect; 
black symbols (*) = PPARα effect. 1 symbol (*) = P < 0.05; 2 symbols (**) = 





significance of a test of a combination of groups (i.e. main effects or two-way 
interactions) as described in the text. n = 8-11 per group. 
Figure 4 Mitochondrial respiratory function from Assay 1 normalised to citrate 
synthase activity. A) Malate and palmitoyl CoA stimulated LEAK respiration 
(CPT1L); B) CPT1-limited OXPHOS (CPT1P); C) OXPHOS supported by the 





mice following normoxia (white bars, 
21% O2) or hypoxia (blue bars, 10% O2), and chloride (open bars, 0.7 mM 
NaCl) or nitrate (striped bars, 0.7 mM NaNO3) supplementation. Error bars 
indicate SEM. 
Δ
 = two-way interaction. Orange symbols (
Δ
) = nitrate effect; 
black symbols (
Δ
) = PPARα effect. 1 symbol (
Δ
) = P < 0.05; 2 symbols (
ΔΔ
) = 
P < 0.01; 3 symbols (
ΔΔΔ
) = P < 0.001. Symbols in brackets (e.g. 
(Δ)
) denote 
significance of a test of a combination of groups (i.e. main effects or two-way 
interactions) as described in the text. n = 4-6 per group. 
Figure 5 Mitochondrial respiratory function from Assay 2 normalised to citrate 
synthase activity. A) Malate and octanoyl carnitine stimulated LEAK 
respiration (OctML); B) OXPHOS supported by the F-pathway via β-oxidation 
(OctMP); C) OXPHOS supported by pyruvate and malate through the N-
pathway via complex I (PMP); D) OXPHOS supported by glutamate and 
malate through the N-pathway via complex I (GMP); E) OXPHOS supported 
by glutamate, malate and succinate through the NS-pathway via complexes I 
and II (GMSP); F) OXPHOS supported by by succinate following the addition 





mice following normoxia (white bars, 21% O2) or 
hypoxia (blue bars, 10% O2), and chloride (open bars, 0.7 mM NaCl) or nitrate 
(striped bars, 0.7 mM NaNO3) supplementation. Error bars indicate SEM. 
Black symbols (*) = PPARα effect. 1 symbol (*) = P < 0.05; 2 symbols (**) = 
P < 0.01; 3 symbols (***) = P < 0.001. n = 4-6 per group.  
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Figure 6 Substrate control ratios. Ratios indicate A) CPT1 control over β-oxidation 
(FCRCPT1); B) the contribution of the F-pathway via β-oxidation to maximal 
OXPHOS (FCRF) and C) the capacity for OXPHOS supported by octanoyl 
carnitine plus malate relative to pyruvate plus malate (FCROct/P), in 




mice, following normoxia (white bars, 21% O2) or hypoxia (blue bars, 10% 
O2), and chloride (open bars, 0.7 mM NaCl) or nitrate (striped bars, 0.7 mM 
NaNO3) supplementation. Error bars indicate SEM. 
Δ
 = two-way interaction; † 
= three-way interaction. Orange symbols (
†








) = PPARα effect. 1 symbol (
†
) = P < 




) = P < 0.001. n = 8-10 per group. 
Figure 7 Enzyme activities in mouse heart tissue homogenates. Maximal activity of 
A) citrate synthase (CS); B) 3-hydroxyacyl dehydrogenase (HADH); C) 





mice, following normoxia (white bars, 21% O2) or 
hypoxia (blue bars, 10% O2), and chloride (open bars, 0.7 mM NaCl) or nitrate 
(striped bars, 0.7 mM NaNO3) supplementation. Error bars indicate SEM. *** 
P < 0.001, hypoxia main effect; 
ΔΔ 
P < 0.01, nitrate effect following 
nitrate/PPARα interaction; 
ΔΔΔ 
P < 0.001, hypoxia effect following 
hypoxia/PPARα interaction; 
ΔΔ
 P < 0.01, PPARα effect following 
nitrate/PPARα interaction; 
ΔΔΔ
 P < 0.01, PPARα effect following 
hypoxia/PPARα interaction. Symbols in brackets denote significance of a test 
of a combination of groups (i.e. main effects or two-way interactions) as 
described in the text. n = 4-5 per group. 
Figure 8 Total pyruvate dehydrogenase (PDH) levels and phosphorylation. Protein 
levels of A) total PDH; and phosphorylation of PDH at E1α site B) serine 232 





mice, following normoxia (white bars, 21% 
O2) or hypoxia (blue bars, 10% O2), and chloride (open bars, 0.7 mM NaCl) or 
nitrate (striped bars, 0.7 mM NaNO3) supplementation. Error bars indicate 
SEM. 
Δ





= hypoxia effect; black symbols (
†
) = PPARα effect. 1 symbol (
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) = P < 0.05 3 symbols (
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